United States

Cummings criticizes Turing’s fake price cut

Friday, December 4, 2015

Rep. Elijah Cummings (D-Md.), ranking member of the House Committee on Oversight and Government Reform, has sent a letter to former hedge fund manager Martin Shkreli, CEO of Turing Pharmaceuticals, condemning his company’s efforts to tout a 50% “price cut” for Daraprim after the company increased the price of the drug in August by 5,000%.

[Read More]

Baxalta opens Global Innovation Center

Friday, December 4, 2015

Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has announced the official opening of its Global Innovation Center in Cambridge, Mass.

[Read More]

Merck, Pfizer receive FDA Breakthrough Therapy for Avelumab

Monday, November 23, 2015

Merck, of Darmstadt, Germany, and Pfizer have announced that the FDA has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen.

[Read More]

PharmaSeek launches oncology-based business

Monday, November 23, 2015

PharmaSeek has launched a new business called The Oncology Hub, an initiative to bring together sponsors, CROs, academic research institutions, major medical centers, oncology networks and stand-alone oncology sites in order to assist with site identification for complex clinical trials.

[Read More]

Halozyme to expand in San Francisco

Thursday, November 19, 2015

Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San Francisco. Halozyme is based in San Diego and currently has about 200 employees.

[Read More]

Viking Therapeutics submits IND application for VK2809

Wednesday, November 18, 2015

Viking Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, has submitted an investigational new drug (IND) application to FDA to conduct a phase II study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

[Read More]

Dyax named ‘Top Place to Work’

Wednesday, November 18, 2015

Dyax, a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, has been named one of the Top Places to Work in Massachusetts by The Boston Globe for the second year in a row.

[Read More]